Dual-target CAR-NK cell therapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new cell therapy made from natural killer (NK) cells that are engineered to attack two targets (GPC3 and B7-H3) found on liver cancer cells. It may be an option for people with advanced liver cancer who have already tried standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced liver cancer (HCC) that cannot be removed by surgery or has spread, and you have already tried at least one standard treatment.
- Your tumor must test positive for two markers called GPC3 and B7-H3 in at least 25% of cells (for GPC3) and 10% of cells (for B7-H3).
- You are generally well enough to be up and about (ECOG score 0 or 1) and your liver function is fairly good (Child-Pugh class A or stable B7).
- You have not had any past cell therapy with CAR-T, CAR-NK, or similar gene-modified cells.
- You do not have active infections or other serious medical conditions that would make treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target cancer cells in advanced biliary tract cancers—including bile duct and gallbladder cancers. The cells are engineered to recognize and attack cancer cells that have specific markers (HER2 and CEA), and this approach may help patients whose cancer has progressed after standard chemotherapy.
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two markers on breast cancer cells. It is for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments and need new options.
This trial tests CAR-T cell therapy (immune cells changed to target GPC-3) for advanced hepatocellular carcinoma, especially when standard treatments no longer work or you cannot tolerate them. If eligible, the goal is to shrink tumors and help you live longer with improved cancer control.
This trial tests whether specially engineered NK cells can find and attack your type of cancer. It is for people with advanced solid tumors that haven't responded to standard treatments.
This trial tests engineered immune cells (CAR-NK cells) designed to target two markers found on melanoma cells. The goal is to help patients with melanoma that has spread or cannot be surgically removed and has not responded to or is unsuitable for standard treatments.
This trial tests a new type of cell therapy (CAR-NK cells) designed to target kidney cancer that has spread or cannot be removed with surgery. The cells are engineered in the lab to recognize and attack cancer cells, and may help patients whose cancer has grown despite previous treatments.
Hear when a new Advanced Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.